Evidence map›Paper›PMID 39669766›Full record

ArticleHeliyon2024

New solutions of time-fractional cancer tumor models using modified He-Laplace algorithm.

Mubashir Qayyum, Efaza Ahmad, Mohamed R Ali

Abstract read
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mubashir QayyumDepartment of Sciences and Humanities, National University of Computer and Emerging Sciences, Lahore, Pakistan.
Efaza AhmadDepartment of Sciences and Humanities, National University of Computer and Emerging Sciences, Lahore, Pakistan.
Mohamed R AliFaculty of Engineering, Benha National University, Obour Campus, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer develops through cells when mutations build up in different genes that control cell proliferation. To treat these abnormal cells and minimize their growth, various cancer tumor samples have been modeled and analyzed in literature. The current study is focused on the investigation of more generalized cancer tumor model in fractional environment, where net killing rate is taken into account in different domains. Three types of killing rates are considered in the current study including time and position dependent killing rates, and concentration of cells based killing rate. A hybrid mechanism is proposed in which different homotopies are used with perturbation technique and Laplace transform. This leads to a convenient algorithm to tackle all types of fractional derivatives efficiently. The convergence and error bounds of the proposed scheme are computed theoretically by proving related theorems. In the next phase, convergence and validity is analyzed numerically by calculating residual errors round the fractional domain. It is observed that computed errors are very less in the entire fractional domain. Moreover, comparative analysis of Caputo, Caputo-Fabrizio (CF), and Atangana-Baleanu (AB) fractional derivatives is also performed graphically to discern the effect of different fractional approaches on the solution profile. Analysis asserts the reliability of proposed methodology in the matter of intricate fractional tumor models, and hence can be used to other complex physical phenomena.

Indexed as

Atangana–Baleanu derivativeCaputo derivativeCaputo-Fabrizio derivativeFractional cancer tumor modelHomotopy perturbationLaplace transform

Identifiers

PMID39669766
PMCPMC11637049

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.